AlphAIalphai — Financial news for AI agents
rttnews.comSEP 32 min read$NYXH

Nyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares Jump

Nyxoah SA (NYXH) reported positive results from its ACCCESS trial for the Genio system in treating sleep apnea with Complete Concentric Collapse (CCC). The study met primary efficacy and safety endpoints, with 77.2% AHI responder rate and 87.7% ODI responder rate. NYXH shares rose 29.14% in overnight trading.

Original reporting
rttnews.com
Published Sep 3, 2026, 6:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 6:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Nyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares Jump — source image
Source · rttnews.com
Decision brief

The 30-second read

$NYXHBullishMed
01

Why it matters

The ACCCESS trial data represent the first positive pivotal results for the Genio system in CCC patients, potentially unlocking a larger market segment.

02

Market read

Positive trial data could drive short‑term stock rally and support longer‑term growth outlook.

03

What to watch

Regulatory timeline for FDA indication expansion could delay commercial impact.

Relevance 9/10Novelty 9/10Timing: today

Background

Nyxoah SA (NYXH) develops hypoglossal neurostimulation devices for obstructive sleep apnea.

Company-level read

Ticker impact

$NYXHBullishHigh confidence
Context

Nyxoah SA reported positive pivotal ACCCESS trial data for its Genio system, meeting primary efficacy and safety endpoints in CCC sleep apnea patients.

Expected impact

Potential upside of 10-15% over the next week as the market digests the data.

Evidence & confidence

First disclosure of statistically significant efficacy in a niche patient group, expanding the device's potential indication.

Market effects

Sector

May broaden the neuromodulation market for sleep apnea therapies.

Regional

U.S. biotech sector could see modest uplift.

Global

Limited to sleep‑apnea device niche.

Counterpoint

What could challenge this read

Skeptics may question long‑term adoption and reimbursement prospects.

Key entities

  • Company
    Nyxoah SA

    Medical device maker focused on sleep apnea treatments.

  • Product
    Genio system

    Battery‑free hypoglossal neurostimulation therapy.

Read at source← All news

Related articles

AUG 5
$NYXHMed

Nyxoah SA (NYXH): Financial results for Q2 2026

Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. ​ Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium –

SEC EDGAR 6-K2 min
JUL 10
$NYXHMed

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.

yahoo.com4 min
JUL 7
$NYXHMed

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.

manilatimes.net6 min
JUN 10
$NYXHMedAI 8/10

Nyxoah Announces Closing of Underwritten Public Offering

Nyxoah SA said it has closed its previously announced underwritten U.S. public offering, selling 55,232,558 ordinary shares at $1.72 (EUR 1.48) each. Gross proceeds are about $95.0 million (EUR 81.9 million). Net proceeds will fund U.S. commercialization, Genio R&D and commercialization, and general corporate purposes; the company also plans to draw EUR 13.8 million from its EIB loan tranche in Q2 2026.

manilatimes.net4 min